← Evidence map

TrialPharmacoEconomics2003

Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.

Silas C Martin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

10 papers cite it

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

this paperpooled ittrialcites it

Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. | OpenQuestion